When Dr Rebecca Robertson first saw the results of her University of Sydney trial, she found herself amazed: cannabidiol—CBD, a non-intoxicating compound from the cannabis plant—had reduced chronic nerve pain by 14 percent over six weeks, substantially outperforming the placebo's 6.5 percent improvement. Some trial participants reported pain reductions exceeding 30 percent. For millions living with neuropathic pain, these findings offer something increasingly rare in pain management: a genuinely encouraging lead.
Chronic neuropathic pain, the kind that arrives from damaged nerves rather than injury itself, has long resisted treatment. About half of all patients find traditional therapies ineffective, leaving them caught in a cycle of persistent burning, tingling, or shooting sensations that disrupt sleep, work, and daily life. In Australia alone, roughly 8.5 percent of the population—roughly 2 million people—lives with chronic neuropathic pain. For them, any treatment that moves the needle matters enormously.
The University of Sydney researchers recruited 40 adults aged 18 and over who were experiencing chronic neuropathic pain from spinal cord injury. Participants received either CBD tablets or placebo tablets indistinguishable in appearance, taste, and smell. The dosage increased gradually throughout the trial, starting at 200 milligrams per day and reaching 800 milligrams by the end of the six-week period. Three times a day on alternate weekdays, participants rated their pain on a standard clinical scale ranging from zero to ten, providing researchers with granular data on pain levels.
What struck Robertson most was not just the 14 percent improvement—significant on its own—but that CBD was well tolerated even at the highest doses, with few serious side effects. This matters because many pain medications carry substantial risks: opioids fuel addiction, some anticonvulsants cause dizziness and confusion, and others lose effectiveness over time as patients develop tolerance. CBD appears to sidestep these pitfalls, at least in this trial.
The results do come with important caveats. Participants were taking multiple medications alongside the trial treatment, and CBD can interact with commonly prescribed drugs—a variable the researchers cannot fully isolate. Additionally, 78 percent of placebo recipients correctly guessed they were receiving the inactive tablet, suggesting their lower expectations might have dampened any placebo effect for that group. These limitations don't erase the findings but hint that future studies must account for medication interactions and better blind participants to treatment assignment.
Robertson's enthusiasm reflects the genuine scarcity of breakthrough pain management therapies. "Chronic neuropathic pain is notoriously hard to treat," she noted, "and to see such strong results in the trial is significant." Co-investigator Professor Iain McGregor echoed this measured optimism while pointing toward the next chapter: understanding why CBD helped some people far more than others, and how it interacts with the medication regimens most chronic pain patients actually take. Long-term, he hopes this foundation will lead to more effective pain management strategies altogether.
The research, published in eClinicalMedicine, represents the kind of careful, methodical work that can shift the landscape for millions. It won't solve neuropathic pain overnight. But for people who have exhausted conventional options, it offers something previously unavailable: scientific evidence that another path exists.